Back to search results

Observational Study for Lung Cancer Organoids

This observational study is creating a collection of lung cancer cells grown in the lab, called patient-derived organoids (PDOs), from people with lung cancer. Researchers want to see if these PDOs can accurately show how a patient's tumor will respond to chemotherapy and targeted treatments. You might be able to join if you are at least 18 years old, have been diagnosed with lung cancer or a lung mass, and are having surgery or systemic treatment. The study aims to collect information from 150 participants. This study does not involve new treatments; it focuses on understanding lung cancer better through these lab models. The status of this study is currently unclear.

Study design
This is an observational study aiming to enroll 150 participants. It involves collecting tumor samples and patient information.
What's involved
If you participate, tumor specimens will be collected during your surgery. You will also complete a questionnaire.
Compensation
Not stated in the trial record.
Follow-up
Your treatment and survival history will be collected over a period of 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03655015

Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer

Recruiting
Not specifiedAges 18+Observational
The University of Texas Health Science Center at San Antonio
~150 participants
Updated 2026-04-20 on ClinicalTrials.gov
What's tested:Lung Tumor Resection

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To establish and characterize a biobank of patient-derived organoids (PDOs), and investigate the potential of PDOs to recapitulate ex vivo responses to chemotherapeutic and targeted agents observed in the clinic.
Measured over 10 years

Conditions

Lung Neoplasm

Explore related trials

Lung Carcinoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Josephine Taverna, MD · PRINCIPAL_INVESTIGATOR · UT Health San Antonio M.D. Anderson Cancer Center

Who to contact

Josephine Taverna, MD
[email protected]
210-450-8234
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure.
Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care
Any clinical stage of lung cancer
Adult patients ≥18 years of age
Able and willing to complete a questionnaire on their environmental/occupational exposures and smoking/alcohol history

Exclusion

At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.

What this trial measures

  • To establish and characterize a biobank of patient-derived organoids (PDOs), and investigate the potential of PDOs to recapitulate ex vivo responses to chemotherapeutic and targeted agents observed in the clinic.10 years

    Establishment of a living biobank of PDOs and the potential of PDOs to repeat their process outside a living organism